Thorne HealthTech, a provider of at-home health tests and nutritional supplements, is working with investment bank CG Sawaya Partners to explore a sale amid interest from other companies and private equity firms, people familiar with the matter told Reuters’ Abigail Summerville. The sources said that no deal is certain and a Thorne spokesperson said the company does not comment on rumors or speculation, Reuters noted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on THRN:
- Thorne jumps 12% to $5.88 after Reuters report of exploring sale
- Thorne HealthTech working with bank to explore sale, Reuters reports
- Thorne HealthTech trading resumes
- Thorne HealthTech trading halted, volatility trading pause
- Thorne HealthTech’s blood sampling device earns CE Mark certification in EU
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue